The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
Open accessAbstract
BACKGROUND: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly prescribed for these patient populations despite scarcity of evidence of clinical effectiveness or cost-effectiveness. We aimed to compare the long-term clinical effectiveness and cost-effectiveness of levetiracetam compared with valproate in participants with newly diagnosed generalised or unclassifiable epilepsy. METHODS: We did an open-label, randomised controlled trial to compare levetiracetam with valproate as first-line treatment for patients with generalised or unclassified epilepsy. Adult and paediatric neurology services (69 centres overall) across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked generalised or unclassifiable seizures. Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation programme with a random element utilising factors. Participants and investigators were aware of treatment allocation. For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5-12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate and 40 mg/kg for levetiracetam. All drugs were administered orally. SANAD II was designed to assess the non-inferiority of levetiracetam compared with valproate for the primary outcome time to 12-month remission. The non-inferiority limit was a hazard ratio (HR) of 1·314, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on valproate. All participants were included in the intention-to-treat (ITT) analysis. Per-protocol (PP) analyses excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analyses included all participants who received one dose of any study drug. This trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64). FINDINGS: 520 participants were recruited between April 30, 2013, and Aug 2, 2016, and followed up for a further 2 years. 260 participants were randomly allocated to receive levetiracetam and 260 participants to receive valproate. The ITT analysis included all participants and the PP analysis included 255 participants randomly allocated to valproate and 254 randomly allocated to levetiracetam. Median age of participants was 13·9 years (range 5·0-94·4), 65% were male and 35% were female, 397 participants had generalised epilepsy, and 123 unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission (HR 1·19 [95% CI 0·96-1·47]); non-inferiority margin 1·314. The PP analysis showed that the 12-month remission was superior with valproate than with levetiracetam. There were two deaths, one in each group, that were unrelated to trial treatments. Adverse reactions were reported by 96 (37%) participants randomly assigned to valproate and 107 (42%) participants randomly assigned to levetiracetam. Levetiracetam was dominated by valproate in the cost-utility analysis, with a negative incremental net health benefit of -0·040 (95% central range -0·175 to 0·037) and a probability of 0·17 of being cost-effectiveness at a threshold of £20 000 per quality-adjusted life-year. Cost-effectiveness was based on differences between treatment groups in costs and quality-adjusted life-years. INTERPRETATION: Compared with valproate, levetiracetam was found to be neither clinically effective nor cost-effective. For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding valproate. FUNDING: National Institute for Health Research Health Technology Assessment Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
Christensen, J., Grønborg, T. K., Sørensen, M. J., Schendel, D., Parner, E. T., Pedersen, L. H., & Vestergaard, M. (2013) · JAMA · doi:10.1001/jama.2013.2270 · Cited by 1,357
Review of statistical methods for analysing healthcare resources and costs
Mihaylova, B., Briggs, A., O'Hagan, A., & Thompson, S. G. (2011) · Health Economics · doi:10.1002/hec.1653 · Cited by 767
Estimating risk for developing epilepsy: A population-based study in Rochester, Minnesota
Hesdorffer, D. C., Logroscino, G., Benn, E. K. T., Katri, N., Cascino, G., & Hauser, W. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a36a · Cited by 324
Trinka, E., Marson, A. G., Van Paesschen, W., Kälviäinen, R., Marovac, J., Duncan, B., Buyle, S., Hallström, Y., Hon, P., Muscas, G. C., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300376 · Cited by 121
Self-citationBonnett, L., Smith, C. T., Smith, D., Williamson, P., Chadwick, D., & Marson, A. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70018-2 · Cited by 69
Self-citation
Cited by
Antiseizure Medications for Adults With Epilepsy: A Review
Kanner, A. M., & Bicchi, M. M. (2022) · JAMA · doi:10.1001/jama.2022.3880 · Cited by 447
Disparities in seizure outcomes revealed by large language models
(2024) · doi:10.1093/jamia/ocae047 · Cited by 17
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“…also been proven that the effectiveness of levetiracetam is lower than that of valpro - ate in the treatment of idiopathic generalized epilepsies [94] and lower than lamotrigine in the treatment of focal epilepsies [95 ], which puts into question its use as a first-line drug in the treatment of…”
Background
Metadata
- Authors
- Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., Baker, G. A., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R., Smith, P. E., Lanyon, K., Manford, M., Chitre, M., Parker, A., Swiderska, N., Appleton, R., Pauling, J., Hughes, A., Gupta, R., Hanif, S., Awadh, M., Ragunathan, S., Cable, N., Cooper, P., Hindley, D., Rakshi, K., Molloy, S., Reuber, M., Ayonrinde, K., Wilson, M., Saladi, S., Gibb, J., Funston, L.-A., Cassidy, D., Boyd, J., Ratnayaka, M., Faza, H., Sadler, M., Al-Moasseb, H., Galtrey, C., Wren, D., Olabi, A., Fuller, G., Khan, M., Kallappa, C., Chinthapalli, R., Aji, B., Davies, R., Foster, K., Hitiris, N., Maguire, M., Hussain, N., Dowson, S., Ellison, J., Sharrack, B., Gandhi, V., Powell, R., Tittensor, P., Summers, B., Shashikiran, S., Dison, P. J., Samarasekera, S., McCorry, D., White, K., Nithi, K., Richardson, M., Brown, R., Page, R., Deekollu, D., Slaght, S., Warriner, S., Ahmed, M., Chaudhuri, A., Chow, G., Artal, J., Kucinskiene, D., Sreenivasa, H., Velmurugan, Zipitis, C. S., McLean, B., Lal, V., Gregoriou, A., Maddison, P., Pickersgill, T., Anderson, J., Lawthom, C., Howell, S., Whitlingum, G., Rakowicz, W., Kinton, L., McLellan, A., Zuberi, S., Kelso, A., Hughes, I., Martland, J., Emsley, H., de Goede, C., Singh, R., Moor, C.-C., Aram, J., Mohanraj, R., Sakthivel, K., Nelapatla, S., Rittey, C., Pinto, A., Leach, J. P., Cock, H., Richardson, A., Houston, E., Cooper, C., Lawson, G., Massarano, A., Burness, C., Marson, A., Smith, D., Wieshmann, U., Dey, I., Sivakumar, P., Yeung, L.-K., Smith, P., Bentur, H., Heafield, T., Mathew, A., Smith, D., & Jauhari, P.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 397
- Issue
- 10282
- Pages
- 1375-1386
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3144446845
- Cited by
- 219
- References
- 7
- FWCI
- 23.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00246-4
- The paper
- Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., Baker, G. A., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R., Smith, P. E., . . . Jauhari, P. (2021). The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)00246-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.